148 related articles for article (PubMed ID: 29768028)
21. Phenotyping drug disposition in oncology.
Opdam FL; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2012 Oct; 38(6):715-25. PubMed ID: 22226243
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
[TBL] [Abstract][Full Text] [Related]
23. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential.
Vishwanathan K; Mair S; Gupta A; Atherton J; Clarkson-Jones J; Edeki T; Das S
Drug Metab Dispos; 2014 May; 42(5):932-42. PubMed ID: 24616266
[TBL] [Abstract][Full Text] [Related]
25. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic protein-drug interactions and implications for drug development.
Huang SM; Zhao H; Lee JI; Reynolds K; Zhang L; Temple R; Lesko LJ
Clin Pharmacol Ther; 2010 Apr; 87(4):497-503. PubMed ID: 20200513
[TBL] [Abstract][Full Text] [Related]
27. [Modulation of nuclear receptors on drug-metabolizing enzymes and transporters].
Liu ZH; Li Y
Yao Xue Xue Bao; 2012 Dec; 47(12):1575-81. PubMed ID: 23460960
[TBL] [Abstract][Full Text] [Related]
28. In vitro methods to support transporter evaluation in drug discovery and development.
Brouwer KL; Keppler D; Hoffmaster KA; Bow DA; Cheng Y; Lai Y; Palm JE; Stieger B; Evers R;
Clin Pharmacol Ther; 2013 Jul; 94(1):95-112. PubMed ID: 23588315
[TBL] [Abstract][Full Text] [Related]
29. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
30. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of the mechanisms of the drug-drug interaction from a view of pharmacogenomics].
Sai Y; Tsuji A
Nihon Rinsho; 2002 Jan; 60(1):74-80. PubMed ID: 11808342
[TBL] [Abstract][Full Text] [Related]
32. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
[TBL] [Abstract][Full Text] [Related]
33. Transporter assays as useful in vitro tools in drug discovery and development.
Volpe DA
Expert Opin Drug Discov; 2016; 11(1):91-103. PubMed ID: 26512742
[TBL] [Abstract][Full Text] [Related]
34. Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes.
Mariappan TT; Shen H; Marathe P
Curr Drug Metab; 2017 Oct; 18(8):757-768. PubMed ID: 28738769
[TBL] [Abstract][Full Text] [Related]
35. [Drug Interactions in Neurology and Psychiatry].
Hase T; Furukori N; Shimoda K
Brain Nerve; 2023 May; 75(5):421-426. PubMed ID: 37194507
[TBL] [Abstract][Full Text] [Related]
36. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
[TBL] [Abstract][Full Text] [Related]
37. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
38. An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis).
Albassam AA; Markowitz JS
Planta Med; 2017 Apr; 83(6):496-508. PubMed ID: 28118673
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
Riley RJ; Wilson CE
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
[TBL] [Abstract][Full Text] [Related]
40. Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance.
Coutant DE; Hall SD
J Clin Pharmacol; 2018 Jul; 58(7):849-863. PubMed ID: 29505093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
